BIMI International Medical Inc. Announces Second Quarter 2023 Financial Results
2023年11月27日 - 10:25PM
BIMI International Medical Inc. (the “Company”), a leading medical
solutions provider, today announced its financial results for the
three months ended June 30, 2023. The Company reported a
significant increase in gross margin underlining the ongoing
success of its business strategy and operational effectiveness.
Revenues for the six months ended June 30, 2023
and 2022 were $8,755,303 and $5,543,745, respectively. Compared
with the same period in 2022, revenue increased by $3,211,558, due
to the inclusion of the revenues of Phenix Bio Inc., which was
acquired on March 15, 2023. The revenues of the Zhongshan,
Qiangsheng, Eurasia, and Minkang hospitals, that were held for
sale, were accounted for separately.
For the six months ended June 30, 2023, and
2022, The company achieved gross margins 52% and 15%, respectively,
reflecting the high margins for the herbal supplements sold by
Phenix Bio Inc..
The Company also reported changes in its cash
position and working capital. On June 30, 2023, BIMI had cash of
$1,931,744 and positive working capital of $6,604,643 as compared
to cash of $2,336,636 and negative working capital of $326,672 on
December 31, 2022.
"We are delighted with the initial success
achieved by Phenix Bio Inc.”, said Mr. Tiewei Song, the CEO of BIMI
International Medical Inc.
About BIMI International Medical
Inc.
BIMI International Medical Inc. is a healthcare
products and services provider, offering a broad range of
healthcare products and related services and operates five private
hospitals in China. For more information, please visit
www.usbimi.com.
Safe Harbor Statement
Certain matters discussed in this news release
are forward-looking statements that involve a number of risks and
uncertainties including, but not limited to, the Company’s ability
to achieve profitable operations, its ability to continue to
operate as a going concern, its ability to continue to meet NASDAQ
continued listing requirements, the effects of the spread of
COVID-19, the demand for the Company’s products and services in the
People’s Republic of China, the continued positive results of the
recently acquired Phenix Bio subsidiary, general economic
conditions and other risk factors detailed in the Company’s annual
report and other filings with the United States Securities and
Exchange Commission.
Investor Relations Contact
Investor Relations Department of BIMI International Medical
Inc.
Email: vinson@usbimi.comTel: +1 949 981 6274
BIMI International Medical (NASDAQ:BIMI)
過去 株価チャート
から 5 2024 まで 6 2024
BIMI International Medical (NASDAQ:BIMI)
過去 株価チャート
から 6 2023 まで 6 2024